Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

495 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-22

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the early longitudinal metabolic effects including insulin sensitivity in HIV-exposed uninfected (HEU) children compared to HIV-unexposed uninfected (HUU) children; as well as to determine differences in the effects of neonatal zidovudine (AZT) vs. nevirapine (NVP) prophylaxis on early longitudinal changes in insulin sensitivity in the first 3 years of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Point-of-Care EID for HIV-Exposed Infants

NCT03824067

HIV/AIDS Infant Morbidity Pediatric HIV Infection +1 more

COMPLETED NA

A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.

NCT00000855

HIV Infections

COMPLETED NA

Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe

NCT03388398

HIV Infections

COMPLETED

A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth

NCT00001007

HIV Infections

COMPLETED PHASE1

Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine

NCT00000828

HIV Infections Pregnancy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will consist of a nested randomized component of HIV-infected (HIV+) and -uninfected (HIV-) pregnant woman/child dyads in Botswana which will take place in Gaborone, Botswana at Botswana-Harvard AIDS Institute Partnership's (BHPs) clinical research facilities. A total of 300 HIV+ pregnant woman/fetus dyads on cART and 150 HIV- pregnant woman/fetus dyads will be evaluated for insulin sensitivity and followed through the child's 3rd birthday. Amongst HEU infants, participants will be randomized at birth 1:1 with 150 to receive neonatal AZT prophylaxis and 150 to receive neonatal NVP prophylaxis. Targeted metabolomics will be used to assess the role intermediary metabolites in insulin resistance and directly assess mitochondrial function using Seahorse XF96e technology. At the time of study enrollment, all women must be willing to exclusively breastfeed for the infant's first 6 months of life. If in utero and neonatal HIV/ARV exposures are found to be associated with derangements in intermediary metabolism such that HEU infants are at increased risk for insulin resistance by 3 years of age, this would impact screening and prevention strategies for diabetes in this vulnerable population and argue for further research to identify prenatal and neonatal ARV regimens with superior PMTCT efficacy but minimal adverse metabolic consequences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Insulin Sensitivity Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Single blind - one party, either the investigator or participant, is unaware of the intervention assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nevirapine

150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis

Group Type EXPERIMENTAL

Nevirapine

Intervention Type DRUG

neonatal 4 weeks prophylactic

Zidovudine

150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis

Group Type ACTIVE_COMPARATOR

Zidovudine

Intervention Type DRUG

neonatal 4 weeks prophylactic

HIV- unexposed Uninfected (HUU) Infants

150 HIV- unexposed Uninfected (HUU) Infants

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zidovudine

neonatal 4 weeks prophylactic

Intervention Type DRUG

Nevirapine

neonatal 4 weeks prophylactic

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AZT NVP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-infected and uninfected pregnant women between 16-36 weeks GA are eligible for study enrollment.
* Women must be 18 years of older and able to provide informed consent for themselves and their infant to participate in the study.
* Participants must be Botswana citizens.
* Women must have evidence of HIV infection status. Women NOT documented as HIV seropositive must have documentation of HIV seronegativity during the present pregnancy at or after 32 weeks GA. Women who have an initial negative HIV test during the present pregnancy which was done at \<32 weeks GA will need to undergo repeat testing on or after 32 weeks GA in accordance with national guidelines.
* HIV-uninfected women must be willing to undergo HIV pre-test counseling, rapid HIV testing and post-test counseling, referred to as HIV Testing and Counseling (HTC) during pregnancy.
* Women must be willing to remain in study area with their infant and attend scheduled study visits as described above until the child's 3rd birthday.
* For HIV-infected women, they must be on TDF/3TC or FTC/EFV or TDF/3TC or FTC/Dolutegravir at time of study enrollment or willing to initiate this treatment and continue throughout the period of breastfeeding, if not for their lifetime.
* At enrollment, all women must be willing to breastfeed exclusively for the first six months of life.